Sonnet BioTherapeutics Holdings Inc. Faces Market Challenges Amid Recent Developments

Sonnet BioTherapeutics Holdings, Inc., a clinical-stage biotechnology company based in Princeton, United States, has recently experienced significant market movements. The company, which specializes in developing innovative targeted biologic drugs using fully human albumin binding technology, has seen its stock price decline by over 15% to $3.49 as of July 3, 2025. This drop places the company’s stock below its close price of $4.15 on July 1, 2025, and well within its 52-week low of $1.08, recorded on May 26, 2025.

In a recent development, Sonnet BioTherapeutics successfully completed the sale of convertible bonds and warrants valued at $2 million on July 2, 2025. This financial maneuver, reported by de.investing.com, indicates the company’s efforts to secure additional funding, potentially to support its ongoing research and development initiatives.

Despite the recent decline in stock price, Sonnet BioTherapeutics remains a point of interest for investors, particularly those focused on penny stocks. According to a report by TipRanks on July 3, 2025, the company is highlighted as one of the top penny stocks to watch. Penny stocks are defined as those trading at or below $5 per share with a market capitalization below $300 million. The company’s inclusion in this list underscores its potential for significant price movements, driven by its innovative approach to cancer treatment development.

The broader market context also reflects notable movements among other stocks. In pre-market trading on July 3, 2025, several companies experienced substantial gains, including Global Interactive Technologies, Inc. (GITS) and MDB Capital Holdings, LLC (MDBH), while others like Inovio Pharmaceuticals, Inc. (INO) and Netcapital Inc. (NCPL) faced declines.

As Sonnet BioTherapeutics navigates these market dynamics, its focus remains on revolutionizing healthcare through its cutting-edge biologic drug development. Investors and market watchers will likely continue to monitor the company’s progress and financial strategies closely.